Q1 2025 · 13F-HR/A
Boxer Capital Management, LLCholdings as filed
Filed 2026-02-17 · accession 0002018299-26-000003
$332.5M
Reported value
28
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $46.6M | 14.0% | 1,317,977 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $31.9M | 9.60% | 450,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $29.5M | 8.86% | 700,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $25.5M | 7.68% | 865,000 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $24.2M | 7.27% | 1,300,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $20.1M | 6.05% | 600,000 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $17.5M | 5.27% | 1,796,341 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $15.6M | 4.69% | 713,000 | Common | SOLE |
| 16934W106 | CMRXEUR | CHIMERIX INC | $15.4M | 4.63% | 1,810,000 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $14.2M | 4.28% | 10,380,999 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $13.2M | 3.97% | 671,358 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $9.7M | 2.91% | 1,732,571 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $9.4M | 2.84% | 1,189,943 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $8.9M | 2.68% | 325,000 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $8.5M | 2.57% | 690,000 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $8.0M | 2.39% | 750,000 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $6.8M | 2.04% | 200,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $6.7M | 2.01% | 563,067 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $6.2M | 1.86% | 1,750,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $4.6M | 1.38% | 1,240,700 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $3.4M | 1.02% | 250,000 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $2.9M | 0.87% | 1,035,000 | Common | SOLE |
| 74065P101 | PRLD | PRELUDE THERAPEUTICS INC | $1.6M | 0.49% | 2,108,014 | Common | SOLE |
| 45783C200 | TIL | INSTIL BIO INC | $1.4M | 0.42% | 80,125 | Common | SOLE |
| 10170A100 | BOLD | BOUNDLESS BIO INC | $377,500 | 0.11% | 250,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $176,900 | 0.05% | 145,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $85,333 | 0.03% | 266,666 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $2,000 | 0.00% | 66,666 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.